A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

My doctor was of the opinion that over-medicalisation of patients was a common problem, and that a high PSA reading might ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

Prostate cancer develops in the prostate gland, a small, walnut-sized organ located below the bladder and in front of the ...

Australia best in region for prostate cancer,but men's mental health at risk - new reportAustralian men live longer after a diagnosis of prostate ...

Adding apalutamide (Erleada) to androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer reduced the risk of developing metastases and castration-resistant disease, ...

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer harboring one or ...

The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...

Progression-free survival on first subsequent therapy (i.e., PFS2) was significantly prolonged with both enzalutamide ...

I've developed crusty red skin patches that itch and seem to get worse when the weather gets colder. What should I do?